Peptide News Digest

#May-26-Embargo

2 stories

Industry · View digest

Memorial Day Monday US News Vacuum — EASL Tuesday May 26 ASCO Embargo, EASL Wednesday May 27 Opens

Monday May 25 is the US Memorial Day federal holiday; SEC filings, FDA actions, US company press releases pause for the day. The week's news cycle picks up Tuesday with ASCO's embargoed virtual press briefing for credentialed media (a preview of Late-Breaking Abstracts ahead of the May 29 Annual Meeting opening in Chicago) and Wednesday with EASL 2026's opening in Barcelona. The combined Tuesday-Wednesday cycle delivers the most concentrated peptide-mechanism data of any week in 2026 — Altimmune pemvidutide IMPACT MASH, Novo Nordisk ESSENCE liver safety, Madrigal Rezdiffra portal hypertension data, Eli Lilly retatrutide MASLD Phase 3 status, and Boehringer survodutide SYNCHRONIZE-1 preview at EASL plus the peptide-oncology cohort at ASCO (Bicycle, Avacta, BriaCell, BioVaxys, Crinetics, Sapience, Corbus). The Hepcludex approval Friday plus the EASL plus ASCO double-meeting structure makes this the highest-volume peptide-news week of 2026 to date.

Industry · View digest

ASCO 2026 Embargoed Virtual Press Briefing Tuesday May 26 — Late-Breaking Abstracts Pre-Meeting Reveal for Credentialed Media Ahead of May 29 Opening

ASCO will hold an embargoed virtual press briefing for credentialed media on Tuesday May 26 to preview Late-Breaking Abstracts being presented during the Annual Meeting that opens Friday May 29 in Chicago. Late-Breaking Abstracts are submitted after the standard abstract deadline and contain data that would not have been available at the regular submission cycle — typically the highest-impact data of the meeting. The briefing covers presentations across the full ASCO program including the peptide-oncology slate that landed in the May 21 abstract release: Bicycle Therapeutics' Duravelo-2 Phase 2 (65% ORR/58% BICR-confirmed), Avacta's AVA6000 Phase 1a/1b in salivary gland cancer (90% disease control rate), Sapience Therapeutics' lucicebtide Phase 2 GBM, BriaCell's Bria-IMT 16.6-month Phase 2 OS, Corbus Pharmaceuticals' CRB-701 Nectin-4 ADC, and Crinetics' CRN09682 SSTR2 NDC BRAVESST2. The May 26 embargo lifts late afternoon to feed press coverage into the Wednesday-Thursday cycle.